Please use this identifier to cite or link to this item:
|Title:||MP53-18: zero sepsis in 608 consecutive transperineal prostate biopsies.|
|Epworth Authors:||Landau, Adam|
|Other Authors:||Huang, Sean|
Tan, Guan Hee
Ong, Wee Loon
Department of Radiology, Epworth Healthcare, Melbourne, Victoria, Australia
Department of Surgery, Epworth Healthcare, Melbourne, Victoria, Australia
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Epworth Prostate Cancer Research Centre, Epworth Healthcare, Richmond, Victoria, Australia
|Citation:||The Journal of Urology; April 2016 vol. 195, Issue 4, Supplement, Page e704.|
|Conference:||The American Urological Association Annual Meeting, 06 May 2016 - 10 May 2016.|
|Conference Location:||San Diego Convention Center, 111 W. Harbor Drive, San Diego, CA 92101.|
|Abstract:||INTRODUCTION AND OBJECTIVES: Sepsis has always been a concern in the traditional transrectal ultrasound (TRUS) guided biopsy of the prostate. However, rates of sepsis following TRUS biopsy have shown to be increasing around the world in addition to the emergence of multiresistant organisms found in rectal flora. As a result, our practice of seven Urologists has switched to transperineal (TP) biopsy. We aim to determine the rate of hospital re-admission in our patients undergoing TP biopsy. METHODS: An ethics approved prospective database of all men undergoing TP biopsy at our practice has been kept including antibiotics used as well as re-admission for infection. RESULTS: A total of 608 TP biopsies were performed between May 2012 and March 2015. Patient demographics include a mean age of 63.5 years (range 41-87), mean PSA of 10.9 (range 0.2 – 83.6) and mean cores taken 25.8 (range 14-36). A total of 538 patients had documented antibiotic usage. Of these, 66.7% (358 patients) received cephazolin only and 31.5% (169 patients) received a fluoroquinolone only. The remaining patients received either a combination of these or another antibiotic. There were no re-admissions for sepsis. CONCLUSIONS: Our data suggests a negligible rate of sepsis with TP biopsy. Furthermore, the use of a single dose of cephalosporin may limit the further development of multiresistant bacteria. Whilst there are other benefits of TP biopsy including increased detection rates and the possibility of MRI fusion, the negligible rate of sepsis alone may be enough to use TP biopsy rather than TRUS biopsy.|
|Affiliated Organisations:||Department of Surgery, Monash University, Melbourne, Victoria, Australia.|
Department of Urology, Alfred Health, Melbourne, Victoria, Australia.
Department of Surgery, Hospital Universiti Kebangsaan Malaysia (HUKM), Malaysia.
|Type of Clinical Study or Trial:||Prospective Study|
|Appears in Collections:||Diagnostic Services|
Epworth Prostate Centre
Files in This Item:
There are no files associated with this item.
Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.